Safety study of STR-P005 for autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your B cells show a marker called CD19 and your blood counts are within a certain range.
- You have not had any cell therapy (like CAR-T) before, or if you did, the engineered cells have disappeared.
- You are not taking certain immune-suppressing drugs now, or you can stop them for a washout period.
- You do not have active infections (like tuberculosis, HIV, hepatitis B or C), uncontrolled heart, lung, kidney, or thyroid problems, or a recent organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cell-targeting treatment called STR-P005 in adults with lupus. The study will check whether it is safe and how well it works for people with lupus who have a specific type of immune cell (CD19-positive B cells) in their blood.
This study tests an experimental drug called AFN50 for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if AFN50 can help control the disease.
This trial tests an investigational drug (STR-P004) given by IV to treat kidney diseases caused by the immune system. It aims to see if the drug is safe and tolerable for patients with conditions like lupus nephritis or ANCA vasculitis.
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called STR-P004 for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and can help fight the cancer.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.